Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 14, 2016; 22(6): 2104-2110
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2104
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2104
Table 1 Patient characteristics n (%)
Prospective group (n = 57) | Retrospective group (n = 613) | P value | |
Age (yr) | 52.4 (17-94) | 58.9 (5-96) | 0.062 |
Gender (M:F) | 35 (61):22 (39) | 320 (52):293 (48) | 0.179 |
Comorbidity | |||
None | 14 (25) | 219 (36) | |
Heart disease | 13 (23) | 127 (21) | |
Hypertension | 19 (33) | 170 (28) | |
Pulmonary disease | 5 (9) | 69 (11) | |
Diabetes mellitus | 4 (7) | 57 (9) | |
Previous pancreatitis | 15 (26) | 38 (6) | < 0.001 |
Duration of pain (h) | 24 (0-504) | 20 (0-0.592) | |
Severe pancreatitis | |||
CRP | 31 (54) | 276 (45) | 0.975 |
CT | 3 (10) | 33 (10) | 0.945 |
Complications | 0.660 | ||
None | 45 (79) | 497 (81) | |
Systemic | 8 (14) | 89 (14.9) | |
Local | 4 (7) | 43 (7.2) | |
Mortality | 1 (2) | 36 (6) | 0.356 |
Severity of pancreatitis | 0.713 | ||
Mild | 50 (88) | 521 (85) | |
Moderate severe | 2 (4) | 54 (9) | |
Severe | 5 (8) | 38 (6) |
Table 2 Investigations during hospital stay and/or follow-up, n (%)
Prospective group (n = 57) | Retrospective group (n = 585 evaluable) | P value | |
All patients with ultrasonography | 51 (89.5) | 420 (71.8) | 0.007 |
All patients with CT | 45 (78.9) | 311 (53.1) | |
All patients with MRI | 32 (56.1) | 196 (33.5) | 0.001 |
US | 5 (8.8) | 142 (24.3) | |
US + CT | 16 (28.1) | 143 (24.4) | |
US + MRI | 7 (12.3) | 86 (14.7) | |
US + CT+ MRI | 23 (40.3) | 49 (8.4) | |
CT alone | 4 (7.0) | 88 (15.4) | |
CT + MRI | 2 (3.5) | 31 (5.3) | |
MRI alone | 0 | 30 (5.1) | |
No imaging | 0 | 16 (2.7) |
Table 3 Cause of acute pancreatitis in the prospective and retrospective group n (%)
Prospective group (n = 57) | Retrospective group (n = 613) | P value | |||
Patients | Patients using medicines1 | Patients | Patients using medicines1 | ||
Bile stone | 23 (40.4) | 13 (57) | 271 (44.2) | 4 (0.1) | < 0.001 |
Bile stone or alcohol | 4 (7.0) | 4 (100) | 14 (2.3) | ||
Alcohol | 6 (10.5) | 1 (17) | 87 (14.2) | 1 (0.1) | |
Hypertriglyceridemia | 3 (5.2) | 3 (100) | 8 (1.3) | ||
ERCP | 1 (1.8) | 0 | 19 (3.1) | ||
PTC | 1 (1.8) | 0 | 0 | ||
Tumor/cancer pancreas | 1 (1.8) | 0 | 9 (1.5) | ||
Pancreas divisum | 2 (3.5) | 1 (50) | 1 (0.2) | ||
Stone in pancreatic duct | 1 (1.8) | 0 | 1 (0.2) | ||
Postoperative pancreatitis | 0 | 0 | 3 (0.5) | ||
Trauma | 0 | 0 | 1 (0.2) | ||
Viral infection | 0 | 0 | 2 (0.3) | ||
Medicines1 | 11 (19.3) | 11 (100) | 15 (2.4) | 15 (100) | |
Unknown2 | 4 (7.0) | 0 | 182 (29.7) | 0 | |
All | 57 (100) | 33 (58) | 613 (100) |
Table 4 Details of drugs used in patients with possible etiologies in the prospective group
Etiology | Generic name | n |
Bile stone (n = 23) | Azathioprine | 1 |
of which medicine users (n = 13) | Simvastatin | 1 |
Diclofenac | 1 | |
Amipril | 1 | |
Enalapril | 1 | |
Drospirenin/etinylostradiol | 1 | |
Simvastatin, Amipril | 1 | |
Atorvastatin, Ezetimib | 1 | |
Amipril | 1 | |
Simvastatin, Amipril, Diclofenac | 1 | |
Methotrexate | 1 | |
Atorvastatin | 1 | |
Simvastatin, | 1 | |
Candesartan hydrochlorothiazide | 1 | |
Simvastatin, | 1 | |
Losartan hydrochlorothiazide | ||
Bile stone or alcohol (n = 4) | Estradiol | 1 |
of which medicine users (n = 4) | Ramipril, Prednisolone | 1 |
Estradiol | 1 | |
Diclofenac | 1 | |
Alcohol (n = 6) | Prednisolone | 1 |
of which medicine users (n = 1) | ||
Hypertriglyceridemia (n = 3) | Gabapentin | 1 |
of which medicine users (n = 3) | Simvastatin | 1 |
Venlafaxine | 1 | |
Medication (n = 11) | Azathioprine | 2 |
of which medicine users (n = 11) | Simvastatin | 1 |
Atorvastatin | 1 | |
Venlafaxine, Ramipril, Asparginase | 1 | |
Atorvastatin | 1 | |
Methotrexate, Prednisolone, Etanercept | 1 | |
Mycofenolic acid, Tacrolimus, Prednisolone | 1 | |
Cyclosporine, Pravastatin, Simvastatin, Ramipril | 1 | |
Diclofenac | 1 | |
Simvastatin, Losartan hydrochlorothiazide | 1 | |
Pancreas divisum (n = 2) | Simvastatin | 1 |
of which medicine users (n = 1) | ||
Total number | 34 |
Table 5 Number of drugs used in patients with medicines as a possible etiology
Use of a single drug | Use of two drugs | Use of three drugs | |||
Name | n | Name | n | Name | n |
Azathioprine | 3 | Simvastatin, Amlodipine | 1 | Simvastatin, Ramipril. | 2 |
Simvastatin | 4 | Simvastatin, Candesartan hydrochlorothiazide | 1 | Diclofenac | |
Gabapentin | 1 | Simvastatin, Losartan hydrochlorothiazide | 2 | Atorvastatin, Ezetimib, Ramipril | 1 |
Methotrexate | 1 | Simvastatin, Pravastatin | 1 | ||
Estradiol | 1 | Ramipril, Prednisolone | 1 | Atorvastatin, Venlafaxine, Ramipril | 1 |
Asparginase | 1 | Methotrexate, Etanercept, Prednisolone | 1 | ||
Diclofenac | 2 | Mycofenolic acid, Tacrolimus, Prednisolone | 1 | ||
Atorvastatin | 2 | ||||
Venlafaxine | 1 | ||||
Furosemide | 1 | ||||
Enalapril | 1 | ||||
Drospirenin etinylostradiol | 1 | ||||
Estradiol | 1 | ||||
Prednisolone | 1 | ||||
Sum | 21 | 6 | 6 |
- Citation: Rashidi M, Røkke O. Prospective evaluation of the cause of acute pancreatitis, with special attention to medicines. World J Gastroenterol 2016; 22(6): 2104-2110
- URL: https://www.wjgnet.com/1007-9327/full/v22/i6/2104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i6.2104